×
About 17,248 results

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00019539

Jun 19th, 2013 - OBJECTIVES: I. Determine the effect of monoclonal antibody VEGF on time to progression, angiogenesis, and overall survival in patients with unresectable advanced renal cell cancer. II. Evaluate serum antibody levels and biologically active vascular endothelial growth factor levels in the plasma of patients treated with this regimen. III. Evaluate the toxicity of this regimen in these patients. ...

Photodynamic Therapy in Treating Patients With Skin Cancer
https://clinicaltrials.gov/ct2/show/NCT00002963

Jan 30th, 2013 - OBJECTIVES: Characterize the penetration of topically applied aminolevulinic acid (ALA) into the lesions of patients with primary basal cell and squamous cell carcinomas. Quantitate the depth of fluorescence achievable with varying application periods of ALA in these patients. Compare the results of tissue fluorescence with surface fluorescence measurements in these patients. OUTLINE: This is a...

FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT00098527

Jul 1st, 2013 - PRIMARY OBJECTIVES: I. Determine the radiographic response rate (complete response and partial response) in patients with refractory adenocarcinoma of the stomach or gastroesophageal junction treated with FR901228 (depsipeptide). SECONDARY OBJECTIVES: I. Determine the median time to progression and progression-free survival of patients treated with this drug. II. Determine the grade 3 and 4 tox...

Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (...
https://clinicaltrials.gov/ct2/show/NCT03222076

Jul 30th, 2018 - Objectives: Primary Objective: 1. To evaluate the safety and tolerability of therapy with nivolumab alone or nivolumab + ipilimumab in resectable HCC in the context of presurgical therapy; to evaluate the safety and tolerability of therapy with nivolumab + ipilimumab in potentially resectable HCC in the context of pre-biopsy therapy. Secondary Objectives: To assess the efficacy of presurgical n...

PIPAC for Peritoneal Metastases of Colorectal Cancer
https://clinicaltrials.gov/ct2/show/NCT03246321

Aug 10th, 2017 - Summary intended for the lay public Background of study: approximately a quarter of the patients who are diagnosed with colorectal cancer and metastases have their metastases in the peritoneum, the so called peritoneal metastases. The vast majority of these patients cannot be cured by surgery, frequently due to too many peritoneal metastases. These incurable patients have a very short life expe...

Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00003175

Dec 3rd, 2013 - OBJECTIVES: I. Determine the response rate and toxic effects of continuous fluorouracil in patients with recurrent locally advanced or metastatic transitional cell urinary tract carcinoma. II. Determine the feasibility of this treatment in this patient population. OUTLINE: Patients receive continuous intravenous fluorouracil by a Baxter Infusor for 24 weeks. Patients are evaluated for complete ...

The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
https://clinicaltrials.gov/ct2/show/NCT03240835

Jun 11th, 2018 - The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma patients with chemoradiotherapy.

Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck
https://clinicaltrials.gov/ct2/show/NCT00002932

Nov 20th, 2014 - OBJECTIVES: I. Determine the percentage of patients for whom a complete course of therapy can be administered using targeted supradose cisplatin chemoradiation in patients with squamous cell carcinoma of the head and neck. II. Determine the partial and complete response rate of cisplatin chemoradiation. III. Determine the incidence of adverse events using cisplatin chemoradiation therapy. IV. D...

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
https://clinicaltrials.gov/ct2/show/NCT00018941

Jun 16th, 2013 - OBJECTIVES: I. Determine the response rate and overall survival of patients with metastatic renal cell carcinoma treated with either low-dose or high-dose intravenous interleukin-2 (IL-2) or subcutaneous IL-2. II. Compare the toxic effects of these 3 regimens in this patient population. OUTLINE: This is a randomized study. Patients are stratified according to presence of renal tumor (yes vs no)...

Combination Chemotherapy in Treating Patients With Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00014534

Jul 13th, 2016 - OBJECTIVES: Primary Compare the survival of patients with completely resected locally advanced transitional cell carcinoma of the bladder treated with adjuvant doxorubicin and gemcitabine followed by paclitaxel and cisplatin vs adjuvant cisplatin and gemcitabine. Secondary Compare the toxicity profiles of these regimens in these patients. OUTLINE: This is a randomized study. Patients are strati...

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00393796

Nov 12th, 2014 - This study is a randomized, blinded, placebo-controlled study evaluating the drug, SUO11248 (SUTENT), for maintenance therapy in advanced urothelial cancer.

Active Surveillance of Papillary Thyroid Microcarcinoma
https://clinicaltrials.gov/ct2/show/NCT02952612

Nov 7th, 2016 - Papillary thyroid microcarcinoma are small thyroid cancer measuring 1cm or less. Most of this tumor are not palpable and are identified either through pathologic examination or from imaging modalities, such as CT scan or thyroid sono. Active surveillance of papillary microcarcinoma is to observe thyroid papillary cancer without immediate surgical approach. The purpose of this study is to unders...

Breast MRI as a Preoperative Tool for DCIS
https://clinicaltrials.gov/ct2/show/NCT00605982

Nov 5th, 2017 - Breast MRI is a fairly new technology, but it has been well studied. It is now used routinely in many patients with breast cancer. It has been shown to be useful in detecting areas of cancer that cannot be seen using other types of scans or tests. The purpose of this study is to see how often MRI can find other areas of cancer in women with one area of breast cancer, and to determine how having...

Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
https://clinicaltrials.gov/ct2/show/NCT00044538

Jun 21st, 2009 - Lung cancer is among the most common cancers in the world and its incidence continues to increase. Chemotherapy for patients with Non-Small Cell Lung Cancer (NSCLC) has been under investigation for several decades and several new drugs with activity in NSCLC have been identified. These include the taxanes, which are among the most commonly used class of chemotherapy agents in clinical oncology ...

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
https://clinicaltrials.gov/ct2/show/NCT00049322

Mar 14th, 2016 - OBJECTIVES: Compare neovessel formation at 8 and 14 weeks after hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma treated with bevacizumab versus no bevacizumab (observation after chemoembolization only). Compare time to progression, objective response rate, and tumor marker progression in patients treated with these regimens. Determine the pharmacokineti...

MRI of the Liver With Eovist
https://clinicaltrials.gov/ct2/show/NCT01215838

Oct 13th, 2013 - Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence of Hepatitis B and C which are known to promote HCC. Patients have a better prognosis (survival outlook) if HCC is found and treated at an early stage. MRI is the best imaging modality for diagnosing HCC. This st...

Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT00067548

Aug 20th, 2009 - This non-randomized, open-label, outpatient clinical trial is designed to assess the safety and efficacy of daily orally administered EKB-569 in subjects with advanced non-small cell lung cancer. Patients must have been previously treated with a platinum- and docetaxel-based therapy either given concurrently or as separate regimens. The primary objective of the study is to assess the clinical a...

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00061178

Oct 18th, 2016 - The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and effective for the treatment of renal cell cancer when other treatments have failed.

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
https://clinicaltrials.gov/ct2/show/NCT00081263

Sep 14th, 2017 - PRIMARY OBJECTIVES: I. To determine the efficacy of celecoxib to induce complete remission (or partial regression to cervical intraepithelial neoplasia (CIN) 1) of CIN 2/3 or CIN 3 as evaluated in the post-treatment excisional biopsy. II. To determine the toxicity of celecoxib (400 mg once daily) as assessed by Common Terminology Criteria for Adverse Events in this patient population of women w...

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT00087412

Feb 27th, 2013 - PRIMARY OBJECTIVES: I. To assess survival in patients with advanced non-small cell lung carcinoma with a Zubrod Performance Status of 2 treated with OSI-774. II. To evaluate the objective tumor response rates (confirmed plus unconfirmed, complete and partial), in patients with advanced non-small cell lung carcinoma with a Zubrod Performance Status of 2 treated with OSI-774. III. To investigate ...